PMCID
stringclasses 24
values | Title
stringclasses 24
values | Sentences
stringlengths 2
40.7k
|
|---|---|---|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Clinical Breast Cancer, 2021.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
21(1): p. 80-91.e7.This reference is of importance because clearly presents an example of covalent-binding TKI to better inhibit the oncogenic pathways in RTK-mutated cancers than the non-covalent binding TKIs in clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Wolska-Washer, A. and T. Robak, Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Expert Review of Hematology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
15(3): p. 183-194.This reference is of importance because clearly presents an example of covalent-binding TKI to better inhibit the oncogenic pathways in cytosolic-kinase-mutated cancers than the non-covalent binding TKI in clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Sobczuk, P., et al., Impact of mutational status on long-term treatment outcomes in patients with advanced gastrointestinal stromal tumors (GIST) treated in the first line with imatinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Annals of Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
33: p. S1238.This referecne is of outstanding importance because this clinical trial comfirms that exon 11 mutation and no PDGFRA exon 18 D842V are correlated with longer median progression free survival when patients are treated by imatinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Blay, J.Y., et al., A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Annals of Oncology, 2024; 10.1016/j.annonc.2024.08.2343.This reference is of outstanding importance because it clearly suggests that 6 years of imatinib treatment is better than 3 years of imatinib treatment in reducing recurrence of GIST.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Previous clinical trial suggests that 3 years of imatinib treatment is better than 1 year of imatinib treatment.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference supports the longer time of imatinib treatment is effective and safe.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Chen, S., et al., Regorafenib third-lined therapy in advanced GISTs: A single center analysis based on different genotypes.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
40(16_suppl): p. 11537-11537.This reference is of outstanding importance because it clearly reviews the clinical efficacy of regorafenib, and supports that exon 17/18 secondary mutation correlates with longer mPFS than non-activation loop mutants.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
The result from this reference also correlates with in vitro data.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Bauer, S., et al., Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
40(34): p. 3918-3928.This reference is of outstanding importance because it reports that ripretinib has the similar effcicay with sunitinib as a second line therapy drug for GIST patients after imatinib failure.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Ripretinib has better safety profile than sunitinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Zalcberg, J.R., et al., Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2024.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
42(3_suppl): p. 748-748.This reference is of outstanding importance because it reports that ripretinib has the similar effcicay with sunitinib as a second line therapy drug for GIST patients after imatinib failure.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Ripretinib has better safety profile than sunitinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Zhou, Y., et al., Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
The Oncologist, 2023.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
28(4): p. e191-e197.This reference is of outstanding importance because it reports that anlotinib is a promising drug for GIST patients after imatinib failure.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference also implies that anlotinib may have similar efficacy to sunitinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Providing evidence that the development of new TKIs to overcome primary and secondary mutants is possible.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
George, S., et al., Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2023.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
41(16_suppl): p. e23508-e23508.This reference is of outstanding importance because it reports that THE-630 is a promising drug for GIST patients after imatinib failure and ≥1 TKI treatment.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Providing evidence that the development of new TKI to overcome primary and secondary mutants is possible.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Li, J., et al., Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2024.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
42(16_suppl): p. 11518-11518.This reference is of importance because it reports that NB003 is a promising drug for GIST patients after imatinib failure.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Providing evidence that the development of new TKIs to overcome primary and secondary mutants is possible.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Qiu, H., et al., Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
40(16_suppl): p. 11513-11513.This reference is of importance because it reports that olverembatinib is a promising drug for SDH-deficient GIST patients.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Providing evidence that the development of new TKI to treat this subtype of wild-type GIST patients is possible.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Kurokawa, Y., et al., Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Annals of Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
33(9): p. 959-967.This reference is of importance because it reports that pimitespib is a promising drug for advanced GIST patients.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
The target of pimitespib is not the traditional KIT/PDGFRA mutants, it targets HSP90.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Providing evidence that development of new drug targeting non-authentic targets could help overcome drug resistance in advanced GIST patients.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Serrano, C., et al., 1489MO A phase Ib/II study of selinexor as single agent and in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Annals of Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
33: p. S1228.This reference is of importance because it reports that selinexor is a promising drug for advanced GIST patients.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Unlike traditional KIT/PDGFRA mutant targets, selinexor targets the XPO1-mediated nuclear export of RNA.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Providing evidence that development of new drug targeting non-authentic targets is possible to overcome drug resistance in advanced GIST patients.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Ligon, J.A., et al., A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Clinical Cancer Research, 2023.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
29(2): p. 341-348.This reference is of importance because it reports that guadecitabine does not achive target response rate in SDH-deficient GIST patients.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
However, it provides preliminary result of targeting the hypermethylation process in SDH-deficient GIST.George, S., et al., A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Clin Cancer Res, 2023.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
29(18): p. 3659-3667.This reference is of importance because it reports that antibody drug conjugate (DS-6157a) is a possible drug for wild-type GIST patients which are resistance to TKI therapy.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Providing evidence that antibody-drug conjugate is a possible drug format to overcome drug resistance for advanced GIST patients.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Liao, Y., et al., The association between fasting blood glucose and prognosis in gastrointestinal stromal tumor patients after curable resection.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Updates in Surgery, 2023.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
75(5): p. 1219-1226.This reference is of importance because it reports that lower blood glucose concentration is beneficial for improving the therapy outcome.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Signifying that linking the TKI therapy with inhibiting metabolism is possible to improve drug efficacy, overcome drug resistance.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Huang, W., et al., A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Mol Genet Genomic Med, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
10(5): p. e1881.This reference is of importance because clearly demonstrates that ALK mutation is one of the oncogenes that contribute to the drug resistance of wild-type GIST in the clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Clearly demonstrates that the non-KIT/PDGFRA mutants are one of the drug resistance mechenisms.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference is of importance because clearly demonstrates that ALK mutation is one of the oncogenes that contribute to the drug resistance of wild-type GIST in the clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Clearly demonstrates that the non-KIT/PDGFRA mutants are one of the drug resistance mechenisms.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Chan, A., et al., Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Clinical Breast Cancer, 2021.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
21(1): p. 80-91.e7.This reference is of importance because clearly presents an example of covalent-binding TKI to better inhibit the oncogenic pathways in RTK-mutated cancers than the non-covalent binding TKIs in clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference is of importance because clearly presents an example of covalent-binding TKI to better inhibit the oncogenic pathways in RTK-mutated cancers than the non-covalent binding TKIs in clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Wolska-Washer, A. and T. Robak, Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Expert Review of Hematology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
15(3): p. 183-194.This reference is of importance because clearly presents an example of covalent-binding TKI to better inhibit the oncogenic pathways in cytosolic-kinase-mutated cancers than the non-covalent binding TKI in clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference is of importance because clearly presents an example of covalent-binding TKI to better inhibit the oncogenic pathways in cytosolic-kinase-mutated cancers than the non-covalent binding TKI in clinical setting.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Sobczuk, P., et al., Impact of mutational status on long-term treatment outcomes in patients with advanced gastrointestinal stromal tumors (GIST) treated in the first line with imatinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Annals of Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
33: p. S1238.This referecne is of outstanding importance because this clinical trial comfirms that exon 11 mutation and no PDGFRA exon 18 D842V are correlated with longer median progression free survival when patients are treated by imatinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This referecne is of outstanding importance because this clinical trial comfirms that exon 11 mutation and no PDGFRA exon 18 D842V are correlated with longer median progression free survival when patients are treated by imatinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Blay, J.Y., et al., A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Annals of Oncology, 2024; 10.1016/j.annonc.2024.08.2343.This reference is of outstanding importance because it clearly suggests that 6 years of imatinib treatment is better than 3 years of imatinib treatment in reducing recurrence of GIST.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Previous clinical trial suggests that 3 years of imatinib treatment is better than 1 year of imatinib treatment.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference supports the longer time of imatinib treatment is effective and safe.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference is of outstanding importance because it clearly suggests that 6 years of imatinib treatment is better than 3 years of imatinib treatment in reducing recurrence of GIST.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Previous clinical trial suggests that 3 years of imatinib treatment is better than 1 year of imatinib treatment.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference supports the longer time of imatinib treatment is effective and safe.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Chen, S., et al., Regorafenib third-lined therapy in advanced GISTs: A single center analysis based on different genotypes.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
40(16_suppl): p. 11537-11537.This reference is of outstanding importance because it clearly reviews the clinical efficacy of regorafenib, and supports that exon 17/18 secondary mutation correlates with longer mPFS than non-activation loop mutants.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
The result from this reference also correlates with in vitro data.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference is of outstanding importance because it clearly reviews the clinical efficacy of regorafenib, and supports that exon 17/18 secondary mutation correlates with longer mPFS than non-activation loop mutants.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
The result from this reference also correlates with in vitro data.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Bauer, S., et al., Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Journal of Clinical Oncology, 2022.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
40(34): p. 3918-3928.This reference is of outstanding importance because it reports that ripretinib has the similar effcicay with sunitinib as a second line therapy drug for GIST patients after imatinib failure.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Ripretinib has better safety profile than sunitinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
This reference is of outstanding importance because it reports that ripretinib has the similar effcicay with sunitinib as a second line therapy drug for GIST patients after imatinib failure.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Ripretinib has better safety profile than sunitinib.
|
PMC11541409
|
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
|
Zalcberg, J.R., et al., Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.